- Home
- ENTA vs DHF Comparison
ENTA vs DHF Comparison
Compare ENTA & DHF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENTA
- DHF
- Stock Information
- Founded
- ENTA 1995
- DHF 1998
- Country
- ENTA United States
- DHF United States
- Employees
- ENTA N/A
- DHF N/A
- Industry
- ENTA Biotechnology: Pharmaceutical Preparations
- DHF Finance Companies
- Sector
- ENTA Health Care
- DHF Finance
- Exchange
- ENTA Nasdaq
- DHF Nasdaq
- Market Cap
- ENTA 154.0M
- DHF 172.4M
- IPO Year
- ENTA 2013
- DHF N/A
- Fundamental
- Price
- ENTA $5.27
- DHF $2.48
- Analyst Decision
- ENTA Buy
- DHF
- Analyst Count
- ENTA 4
- DHF 0
- Target Price
- ENTA $17.25
- DHF N/A
- AVG Volume (30 Days)
- ENTA 194.0K
- DHF 451.1K
- Earning Date
- ENTA 05-20-2025
- DHF 01-01-0001
- Dividend Yield
- ENTA N/A
- DHF 7.65%
- EPS Growth
- ENTA N/A
- DHF N/A
- EPS
- ENTA N/A
- DHF N/A
- Revenue
- ENTA $66,590,999.00
- DHF N/A
- Revenue This Year
- ENTA N/A
- DHF N/A
- Revenue Next Year
- ENTA N/A
- DHF N/A
- P/E Ratio
- ENTA N/A
- DHF N/A
- Revenue Growth
- ENTA N/A
- DHF N/A
- 52 Week Low
- ENTA $4.09
- DHF $2.06
- 52 Week High
- ENTA $17.24
- DHF $2.39
- Technical
- Relative Strength Index (RSI)
- ENTA 45.38
- DHF 55.04
- Support Level
- ENTA $4.96
- DHF $2.45
- Resistance Level
- ENTA $6.23
- DHF $2.50
- Average True Range (ATR)
- ENTA 0.33
- DHF 0.03
- MACD
- ENTA -0.01
- DHF 0.01
- Stochastic Oscillator
- ENTA 24.41
- DHF 81.58
About ENTA Enanta Pharmaceuticals Inc.
Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.
About DHF BNY Mellon High Yield Strategies Fund
BNY Mellon High Yield Strategies Fund is a diversified, closed-end management investment company. The fund's primary investment objective is to seek high current income and its secondary objective is capital appreciation. It invests predominantly in fixed-income securities of below-investment-grade credit quality.